Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
#f |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1/27/25 18:15 | 1/24/25 | XFOR | Health | BioPrd | Biological Products, (No Diag | Ragan Paula | MA | DO | P,CEO | 6 | S | -262 | 0.5819 | 0 | -451 | 1,087 | D | |||||||||||||||
1/27/25 18:15 | 1/24/25 | XFOR | Health | BioPrd | Biological Products, (No Diag | Mostafa Adam S. | MA | O | CFO | 4 | S | -235 | 0.6098 | 0 | -386 | 53 | D | |||||||||||||||
1/27/25 18:15 | 1/24/25 | XFOR | Health | BioPrd | Biological Products, (No Diag | Baldry Mark | MA | O | Chief Co | 2 | S | -20 | 0.4902 | 0 | -40 | 94 | D | |||||||||||||||
1/27/25 18:15 | 1/24/25 | XFOR | Health | BioPrd | Biological Products, (No Diag | Dibiase Mary | MA | O | COO | 5 | S | -67 | 0.6040 | 0 | -112 | 491 | D | |||||||||||||||
1/27/25 18:15 | 1/24/25 | XFOR | Health | BioPrd | Biological Products, (No Diag | Arbet-Engels Christophe | MA | O | Chief Me | 1 | S | -5 | 0.4546 | 0 | -12 | 14 | D | |||||||||||||||
10/8/24 16:44 | 10/7/24 | XFOR | Health | BioPrd | Biological Products, (No Diag | Taveras Arthur | MA | O | Chief Sc | 3 | S | -57 | 0.6162 | 0 | -92 | 388 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |